Preliminary clinical trial with a new hypotensive, guanabenz, in a group of hypertensive patients.
In a small preliminary clinical trial of guanabenz in 16 hypertensives also under treatment with diuretics (hydrochlorothiazide and amiloride), blood pressure was safely and completely controlled in 10 (64%), the criterion for "control" being a reduction to the strict level specified by the Society of Actuaries (130/85 m lambda Hg). The dosage of guanabenz was adjusted upward from 16 mg/day until blood pressure normalized or side effects intervened. The 16 patients accumulated 97 months of guanabenz treatment. The 6 unsuccessful cases included only 2 outright therapeutic failures; the other 4 patients discontinued treatment for various reasons: dry mouth and nausea (with good blood pressure reduction); aggravation of existing depression; or generalized urticaria. The fourth patient discontinued for reasons unknown.
D000368:Aged; D000584:Amiloride / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006143:Guanabenz / Q000008:administration & dosage* / Q000009:adverse effects; D006146:Guanidines / Q000008:administration & dosage*; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D006146:Guanidines; D006852:Hydrochlorothiazide; D000584:Amiloride; D006143:Guanabenz